Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00066248 · ClinicalTrials.gov registry record · Phase 2
Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment
A Phase 2 study, sponsored by University of South Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT00066248 is a Phase 2 study that has completed, run by University of South Florida. The registered enrollment target is 70 participants.
The verdict
NCT00066248, a Phase 2 study, has completed, sponsored by University of South Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
RATIONALE: Cyproheptadine and megestrol may improve appetite and help prevent weight loss in children with cancer. PURPOSE: This phase II trial is studying how well cyproheptadine and megestrol work in improving appetite and preventing weight loss in children with cachexia caused by cancer or cancer treatment.
Interventions
- DRUG megestrol acetate
- DRUG cyproheptadine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2003-06 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00066248
The ClinicalTrials.gov registry entry for NCT00066248 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of South Florida, which has 252 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which megestrol acetate is the first listed.
NCT00066248 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00066248 about?
NCT00066248 is a clinical study titled "Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment". RATIONALE: Cyproheptadine and megestrol may improve appetite and help prevent weight loss in children with cancer. PURPOSE: This phase II trial is studying how well cyproheptadine and megestrol work in improving appetite and preventing weight loss in children with cachexia caused by cancer or cance...
What is the current status of trial NCT00066248?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2003-06. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00066248?
The interventions under investigation include: megestrol acetate (DRUG), cyproheptadine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00066248?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.